Bladder cancer epidemiology and demographics

Jump to navigation Jump to search

Bladder cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Bladder cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Electrocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Biopsy

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Bladder cancer epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Bladder cancer epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Bladder cancer epidemiology and demographics

CDC on Bladder cancer epidemiology and demographics

Bladder cancer epidemiology and demographics in the news

Blogs on Bladder cancer epidemiology and demographics

Directions to Hospitals Treating Bladder cancer

Risk calculators and risk factors for Bladder cancer epidemiology and demographics

Steven C. Campbell, M.D., Ph.D.; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [1]

Overview

Epidemiology and Demographics

Prevalence

  • In the United States, the age-adjusted prevalence of bladder cancer is 130.5 in 2011.[1]

Incidence

  • The delay-adjusted incidence of bladder cancer in 2011 was estimated to be 20.74 per 100,000 persons in the United States.[1]
  • In 2011, the age-adjusted incidence of bladder cancer was 20.13 per 100,000 persons in the United States.[1]

Age

  • While the overall age-adjusted incidence of bladder cancer in the United States between 2007 and 2011 is 20.5 per 100,000, the age-adjusted incidence of bladder cancer by age category is:[1]
    • Under 65 years: 5.4 per 100,000
    • 65 and over: 124.7 per 100,000

Gender

  • In the United States, the age-adjusted prevalence of bladder cancer by gender in 2011 is:[1]
    • In males: 228.9 per 100,000
    • In females: 56.6 per 100,000
  • In the United States, the delay-adjusted incidence of bladder cancer by gender in 2011 is:[1]
    • In males: 36.24 per 100,000 persons
    • In females: 8.98 per 100,000 persons
  • In the United States, the age-adjusted incidence of bladder cancer by gender on 2011 is:[1]
    • In males: 35.18 per 100,000 persons
    • In females: 8.72 per 100,000 persons
  • Shown below is an image depicting the delay-adjusted incidence and observed incidence of bladder cancer by gender and race in the United States between 1975 and 2011. These graphs are adapted from SEER: The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.[1]

Delay-adjusted incidence and observed incidence of bladder cancer by gender and race in the United States between 1975 and 2011

Race

  • Shown below is a table depicting the age-adjusted prevalence of bladder cancer by race in 2011 in the United States.[1]
All Races White Black Asian/Pacific Islander Hispanic
Age-adjusted prevalence 130.5 per 100,000 148.2 per 100,000 62.9 per 100,000 58.7 per 100,000 64.4 per 100,000
  • Shown below is an image depicting the incidence of bladder cancer by race in the United States between 1975 and 2011.[1]

Incidence of bladder cancer by race in the United States between 1975 and 2011

API: Asian/Pacific Islander; AI/AN: American Indian/ Alaska Native

Developed Countries

  • The incidence of bladder cancer is higher in Western countries as compared to developing countries.[2]

Developing Countries

  • In the late 1980's and early 1990's, approximately one third of cancer cases in Egypt were cases of bladder cancer. Given the improved treatment of schistosomiasis in Egypt, the incidence of bladder cancer has been decreasing.[5]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
  2. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P; et al. (2013). "Epidemiology and risk factors of urothelial bladder cancer". Eur Urol. 63 (2): 234–41. doi:10.1016/j.eururo.2012.07.033. PMID 22877502.
  3. 3.0 3.1 Shokeir AA (2004). "Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment". BJU Int. 93 (2): 216–20. PMID 14690486.
  4. el-Mawla NG, el-Bolkainy MN, Khaled HM (2001). "Bladder cancer in Africa: update". Semin Oncol. 28 (2): 174–8. PMID 11301380.
  5. Zaghloul MS (2012). "Bladder cancer and schistosomiasis". J Egypt Natl Canc Inst. 24 (4): 151–9. doi:10.1016/j.jnci.2012.08.002. PMID 23159285.

Template:WH Template:WS